ADAGENE INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.41 USD | +3.43% |
|
+2.55% | +24.77% |
| Mar. 29 | Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 29 | Adagene Inc. Announces Board Changes | CI |
Chart calendar Adagene Inc.
26740e8b637643f3fd42f4c75870852.3jy8-_0FIaYXC9WHB15XGpe6M-G0eQcLo1tp7upowV0.52iMqa9EdddCfIq2RBU-QMLiR5TNDH9zxThfj9MBlnCRCI_Jl11gwURI7Q~1e9de17210c1fa17410c90fa623c63e7
Upcoming events on Adagene Inc.
Past events on Adagene Inc.
| 2024-03-29 09:00 am | Q4 2023 Earnings Release |
| 2024-03-12 01:40 pm | Leerink Partners Global Biopharma Conference |
| 2024-01-20 09:30 am | American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Abstract Number: 127 |
| 2023-11-03 12:00 pm | SITC Conference - Abstract Number: 847 |
| 2023-09-22 12:00 pm | Society for Immunotherapy of Cancer (SITC) Webinar “Modulation of Tregs in Clinical Trials” |
| 2023-09-13 12:00 pm | H.C. Wainwright Global Investment Conference |
| 2023-09-11 04:15 pm | Morgan Stanley Global Healthcare Conference |
| 2023-08-31 07:32 am | Q2 2023 Earnings Release |
| 2023-04-18 09:00 am | American Association for Cancer Research Meeting - Abstract No CT227 |
| 2023-04-18 09:00 am | American Association for Cancer Research Meeting - Abstract No CT233 |
| 2023-04-17 01:30 pm | American Association for Cancer Research Meeting - Abstract No 2930 |
| 2023-03-28 04:30 pm | Q4 2022 Earnings Release |
| 2023-01-09 02:30 pm | Biotech Showcase |
| 2022-11-10 09:00 am | Society for Immunotherapy of Cancer Meeting - Abstract Number 753 |
| 2022-11-10 09:00 am | Society for Immunotherapy of Cancer Meeting - Abstract Number 773 |
| 2022-09-08 | European Society for Medical Oncology Congress |
| 2022-08-30 05:25 pm | Interim 2022 Earnings Release |
| 2022-06-12 | Goldman Sachs Global Healthcare Conference |
| 2022-06-08 04:30 pm | Jefferies Healthcare Conference |
| 2022-05-18 | Berenberg Emerging Biotech Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,48 | 0,70 0,87 -19.44% | 10,2 6,69 52.1% | 9,29 10,5 -11.28% | 18,1 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -32,2 -33,3 3.44% | -71,2 -70,5 -1.1% | -82,8 -99,1 16.47% | 0,00 0,00 - | -50,9 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -43,2 -36,6 -18.03% | -72,4 -70,5 -2.68% | -83,9 -99,8 15.93% | -23,7 -82,5 71.24% | -50,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -71,5 -78,0 8.36% | -79,5 -83,9 5.21% | 0,00 0,00 - | -49,1 |
|
Net income Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -73,2 -78,0 6.18% | -80,0 -84,2 4.98% | -18,9 0,00 - | -49,1 |
|
EPS USD | Released Forecast Spread | -1,10 | 0,00 0,00 - | -1,46 -1,43 -2.1% | -1,48 -1,53 2.95% | 0,00 0,00 - | -0,88 |
| Announcement Date | 22/09/20 | 31/03/21 | 31/03/22 | 28/03/23 | 29/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,36 11,0 -87.65% | 4,41 11,0 -59.91% | 8,82 10,0 -11.84% | 3,92 13,8 -71.47% | 5,37 6,79 -20.9% | 17,3 0,00 - |
|
EBIT Million USD | Released Forecast Spread | -37,5 -16,5 -127.3% | -17,4 -10,3 -68.9% | -34,9 -31,3 -11.37% | -48,1 -34,2 -40.42% | -35,8 -37,3 3.87% | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -32,4 -50,7 36.05% | |||||
|
Net income Million USD | Released Forecast Spread | -32,3 -50,7 36.25% | -4,11 | ||||
|
EPS USD | Released Forecast Spread | -0,87 -0,42 -107.14% | -0,61 -0,66 6.87% | ||||
| Announcement Date | 26/08/21 | 31/03/22 | 31/03/22 | 31/08/22 | 28/03/23 | 31/08/23 |
More events
Past sector events for Adagene Inc.
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ADAG Stock
- Calendar Adagene Inc.
